



**XII Simpósio Internacional de Endoscopia Digestiva da SOBED**  
**XIII Congresso Norte-Nordeste de Gastroenterologia**  
**XXXIII Congresso da Regional Norte-Nordeste de Coloproctologia**  
**I Congresso Norte-Nordeste do Colégio Brasileiro de Cirurgia Digestiva**  
**VI GastroParaíba**

**17 a 19 de maio | Centro de Convenções de João Pessoa | PB | 2018**


# **Metástase hepática de tumor colorretal: qual a evidência atual?**

**Orlando Jorge M. Torres**

Professor Titular

Chefe do Serviço de Cirurgia do Aparelho Digestivo  
Universidade Federal do Maranhão


# Ressecção hepática



□ A ressecção hepática esteve associada com aumento na sobrevida.

## Resultados em meta colo-retal

**FIGURE 2**



# Critérios de irresssecabilidade


## Antes

- ☐ Quatro ou mais metástases
- ☐ Tamanho > 5 cm
- ☐ Doença bilateral
- ☐ Margem cirúrgica < 1 cm
- ☐ Doença extra-hepática
- ☐ Escore prognóstico

## Depois


- ☐ Incapacidade de ressecção R0
- ☐ Margem histológica positiva
- ☐ Inabilidade de ressecar toda doença detectável
- ☐ Progressão da doença apesar da QT


# Equipe multidisciplinar




# Qumioterapia


- ❑ Promover downsize e elevar a taxa de ressecção curativa.
- ❑ Converter doença irressecável para ressecável.
- ❑ Identificar os respondedores em pacientes de risco elevado de recorrência, para pós-operatória.
- ❑ Pacientes com múltiplas lesões, selecionar quem progride apesar da QT, que podem não se beneficiar da ressecção.










# Remanescente hepático








68a, fem, seg 2/3 prévia,  
quimioterapia
















# Volumetria








Cortesia: Prof. Paulo Herman (USP)



Cortesia: Prof. Paulo Herman (USP)





Cortesia: Prof. Paulo Herman (USP)

# Hepatotoxicidade


Esteatohepatite

Irinotecan







**“blue liver”  
Oxaliplatina**




# Embolização da veia porta



# EMBOLIZAÇÃO DA VEIA PORTA

## EMBOLIZAÇÃO DA VEIA PORTA




Makuuchi M, et al. Surgery 1990



## Embolização da veia porta



# Ligadura da veia porta







Ligadura da veia porta D



# Liver Metastasis Resection: A Simple Technique That Makes It Easier


## Metastasectomia


Eduardo de Santibañes • Rodrigo Sánchez Clariá •  
Martín Palavecino • Axel Beskow • Juan Pekolj














1. Quimioterapia
2. Embolização da veia porta
3. Operações dois tempos










fígado “Ver a vida pelo lado bom” mor no tumor”

# METÁSTASES HEPÁTICAS: LIMITES PARA RESSECÇÃO


## **EMBOLOGIZAÇÃO DA VEIA PORTA**

Makuuchi M, et al. Surgery 1990




## **HEPATECTOMIA EM DOIS TEMPOS**

Adam R, et al. Ann Surg 2000




## **HEPATECTOMIA EM DOIS TEMPOS + EVP**

Jaeck D, et al. Ann Surg 2004



## **HEPATECTOMIA EM DOIS TEMPOS + LVP**

Belghiti J, et al. Hepatology 2008




# Hepatectomia em dois tempos

ANNALS OF SURGERY  
Vol. 232, No. 6, 777-785  
© 2000 Lippincott Williams & Wilkins, Inc.

## Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors

René Adam, MD, PhD, Alexis Laurent, MD, Daniel Azoulay, MD, PhD, Denis Castaing, MD, and Henri Bismuth, MD, FACS (Hon)

*From the Centre Hépatobiliaire, Hôpital Paul Brousse, Villejuif, and Université Paris-Sud, France*



# Margem de ressecção

ORIGINAL ARTICLE


---

## One-Millimeter Cancer-Free Margin Is Curative for Colorectal Liver Metastases

*A Propensity Score Case-Match Approach*

*Zaed Z. R. Hamady, PhD, FRCS,\*† J. Peter A. Lodge, MD, FRCS,† Fenella K. Welsh, FRCS,\*  
Giles J. Toogood, DM, FRCS,† Alan White, MRCS,† Timothy John, FRCS,\* and Myrddin Rees, FRCS\**

# Margem de ressecção




## ORIGINAL ARTICLE

**Twelve-year experience of “radical but conservative” liver surgery for colorectal metastases: impact on surgical practice and oncologic efficacy**

Guido Torzilli, Luca Viganò, Andrea Gatti, Guido Costa, Matteo Cimino, Fabio Procopio, Matteo Donadon & Daniele Del Fabbro


Department of Surgery – Division of Hepatobiliary & General Surgery, Humanitas University, School of Medicine, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, Italy



# Doença extra-hepática



- ☐ Pulmão
- ☐ Ovário
- ☐ Osso
- ☐ Linfonodo do pedículo
- ☐ Peritôneo

# Ressecções vasculares






Cortesias: Dr. Eduardo de Santibanes

# Ressecção de veia cava



Cortesia: Dr. Eduardo de Santibanes



Cortesía: Dr. Eduardo de Santibanes

# A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases

## *The RAPID Concept*


*Pål-Dag Line, MD, PhD,\* Morten Hagness, MD, PhD,\* Audun Elnaes Berstad, MD, PhD,† Aksel Foss, MD, PhD,\*§  
and Svein Dueland, MD, PhD‡*




---

**Objective:** Selected patients with nonresectable colorectal liver metastases


20% of the patients become surgically resectable. We have demon-

**Transplante hepático**






# ALPPS






## Cirurgia 1




7-10 dias

## Cirurgia 2





Cortesia Dr. Sanjay Govil - Bangalore (India)



# Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings

*Andreas A. Schnitzbauer, MD,\* Sven A. Lang, MD,\* Holger Goessmann, MD,† Silvio Nadalin, MD,§  
Janine Baumgart, MD,|| Stefan A. Farkas, MD,\* Stefan Fichtner-Feigl, MD,\* Thomas Lorf, MD,¶  
Armin Goralcyk, MD,¶ Rüdiger Hörbelt, MD,# Alexander Kroemer, MD,\* Martin Loss, MD,\* Petra Rümmele, MD,‡  
Marcus N. Scherer, MD,\* Winfried Padberg, MD,# Alfred Königsrainer, MD,§ Hauke Lang, MD,||  
Aiman Obed, MD,¶ and Hans J. Schlitt, MD\**

ABCDDV/898

ABCD Arq Bras Cir Dig  
2013;26(1):40-43

Original Article



## ASSOCIATING LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS): THE BRAZILIAN EXPERIENCE



*Ligadura da veia porta associada à bipartição do fígado para hepatectomia em dois estágios (ALPPS): experiência Brasileira*


Orlando Jorge Martins TORRES<sup>1</sup>, Eduardo de Souza Martins **FERNANDES**<sup>2</sup> Cassio Virgílio Cavalcante **OLIV**  
Cristiano Xavier **LIMA**<sup>4</sup>, Fabio Luiz **WAECHTER**<sup>5</sup>, Jose Maria Assunção **MORAES-JUNIOR**<sup>1</sup>,  
Marcelo Moura **LINHARES**<sup>6</sup>, Rinaldo Danese **PINTO**<sup>7</sup>, Paulo **HERMAN**<sup>8</sup>, Marcel Autran Cesar **MACHAD**

**12 e 12,8% Mortalidade**










Numbers at risk

|                                |    |    |    |    |
|--------------------------------|----|----|----|----|
| Age $\leq 60$ + CLRM<br>(n=78) | 71 | 30 | 13 | 10 |
| Others<br>(n=121)              | 72 | 29 | 8  | 0  |



## BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES

*Consenso brasileiro de tratamento multidisciplinar de metástase hepática de origem colorretal  
Módulo 3: Controvérsias e metástases irresssecáveis*

Orlando Jorge Martins **TORRES**<sup>1,2,6</sup>, Márcio Carmona **MARQUES**<sup>2,6</sup>, Fabio Nasser **SANTOS**<sup>1</sup>, Igor Correia de **FARIAS**<sup>2,6</sup>,  
Anelisa Kruschewsky **COUTINHO**<sup>3</sup>, Cássio Virgílio Cavalcante de **OLIVEIRA**<sup>1,4,5</sup>, Antonio Nocchi **KALIL**<sup>1,2,4,6</sup>,  
Celso Abdon Lopes de **MELLO**<sup>3</sup>, Jaime Arthur Pirola **KRUGER**<sup>1,4,5,6</sup>, Gustavo dos Santos **FERNANDES**<sup>3</sup>,  
Claudemiro **QUIREZE JR**<sup>1,4,5,6</sup>, André M. **MURAD**<sup>3</sup>, Milton José de **BARROS E SILVA**<sup>3</sup>,  
Charles Edouard **ZURSTRASSEN**<sup>\*</sup>, Helano Carioca **FREITAS**<sup>3</sup>, Marcelo Rocha **CRUZ**<sup>3</sup>, Rui **WESCHENFELDER**<sup>3</sup>,  
Marcelo Moura **LINHARES**<sup>1,4,5,6</sup>, Leonaldson dos Santos **CASTRO**<sup>1,2,6</sup>, Charles **VOLLMER**<sup>6</sup>,  
Elijah **DIXON**<sup>6</sup>, Héber Salvador de Castro **RIBEIRO**<sup>1,2,6</sup>, Felipe José Fernandez **COIMBRA**<sup>1,2,5,6</sup>

### ALPPS

- ❑ Alternative for two-stage hepatectomy
- ❑ Rescue surgery – after PVE

## ALPPS: PAST, PRESENT AND FUTURE

*ALPPS: passado, presente e futuro*

Orlando Jorge M **TORRES**<sup>1</sup>, Eduardo S M **FERNANDES**<sup>2</sup>, Paulo **HERMAN**<sup>3</sup>

<sup>1</sup>Universidade Federal do Maranhão (Federal University of Maranhão), São Luís, MA; <sup>2</sup>Hospital Adventista Silvestre, Rio de Janeiro, RJ, Brazil;

<sup>3</sup>Universidade de São Paulo (University of São Paulo), São Paulo, SP, Brazil.

**C**omplete tumor resection in the liver is the only chance to obtain long-term survival in patients with hepatic tumor or metastasis from other primary cancers. In patients with a large load of tumor within the liver, multiple strategies have been employed to improve resection, especially when a small liver remnant is expected. Staged hepatectomies, in

- ☐ Discutir em reunião multidisciplinar
- ☐ Remanescente < 30%
- ☐ Resgate após falha na embolização de veia porta
- ☐ Evitar em colangiocarcinoma
- ☐ Reduzir morbidade e mortalidade



## The ALPPS procedure for hepatocellular carcinoma larger than 10 centimeters

Orlando Jorge M. Torres\*, Rodrigo Rodrigues Vasques, Thiago Henrique S. Silva, Miguel Eugenio L. Castelo-Branco, Camila Cristina S. Torres

Department of Digestive Surgery, Federal University of Maranhão, São Luiz, MA, Brazil

### ARTICLE INFO

#### Article history:

Received 10 June 2016

### ABSTRACT

**INTRODUCTION:** The only means of achieving long-term survival in hepatocellular carcinoma is complete tumor resection or liver transplantation. Patients with large hepatocellular carcinomas are currently




Fig. 2. ALPPS first procedure with plastic bag.



Fig. 3. CT 15 days after the first procedure.



Fig. 4. Final aspect of the liver remnant.

# The ALPPS Risk Score

## *Avoiding Futile Use of ALPPS*

*Michael Linecker, MD,\* Gregor A. Stavrou, MD,†‡ Karl J. Oldhafer, MD,†‡ Robert M. Jenner, MD,†  
Burkhardt Seifert, PhD,§ Georg Lurje, MD,¶ Jan Bednarsch, MD,¶ Ulf Neumann, MD,¶  
Ivan Capobianco, MD,|| Silvio Nadalin, MD,|| Ricardo Robles-Campos, MD,\*\*  
Eduardo de Santibañes, MD, PhD, FACS,†† Massimo Malagó, MD,‡‡ Mickael Lesurtel, MD, PhD,\*  
Pierre-Alain Clavien, MD, PhD, FACS,\* and Henrik Petrowsky, MD, FACS\**

---

**Objectives:** To create a prediction model identifying futile outcome in

**Conclusions:** Both models have an excellent prediction to assess the individual risk of futile outcome after ALPPS surgery and can be used to avoid

TABLE 3. Risk Modeling

|                                          | Risk Points | Regression Coefficient | Odds Ratio (95% CI) | <i>P</i> |
|------------------------------------------|-------------|------------------------|---------------------|----------|
| <b>Pre-stage 1 variables*</b>            |             |                        |                     |          |
| Tumor type <sup>†</sup>                  |             |                        |                     |          |
| CRLM (reference)                         | 0           | 0.000                  | 1.000               |          |
| Non-CRLM/nonbiliary                      | 1           | 0.655                  | 1.925 (0.808–4.585) | 0.139    |
| Biliary                                  | 2           | 1.326                  | 3.767 (1.800–7.882) | <0.001   |
| Age ≥67 yr                               | 3           | 1.735                  | 5.668 (2.843–11.30) | <0.001   |
| Intercept pre-stage 1                    |             | −5.3                   |                     |          |
| <b>Pre-stage 2 variables<sup>‡</sup></b> |             |                        |                     |          |
| Pre-stage 1 score, per point             | 0.66        | 0.665                  | 1.925 (1.527–2.426) | <0.001   |
| Interstage complications ≥3b             | 1.2         | 1.209                  | 3.350 (1.280–8.769) | 0.014    |
| Pre-stage 2 bilirubin <sup>§</sup>       | 1.5         | 1.496                  | 4.439 (1.699–11.60) | 0.002    |
| Pre-stage 2 creatinine <sup>  </sup>     | 1.7         | 1.696                  | 5.454 (1.606–18.52) | 0.007    |
| Intercept pre-stage 2                    |             | −6.8                   |                     |          |

### ❑ Pre-stage I

### Ponto

Não coloretal/biliar

1

Biliary surgery (Cholangiocarcinoma)

2

Age ≥ 67 yr



3


### ❑ Pre-stage II

Complications ≥ 3b

Bilirubin

Creatinine





| Risk | Score |
|------|-------|
| 5%   | 3.9   |
| 10%  | 4.7   |
| 20%  | 5.5   |
| 50%  | 6.9   |

### Liver surgery: Clinical

FP26.08

### Performance Validation of the ALPPS Risk Model

**M. Linecker**<sup>1</sup>, P. Kambakamba<sup>1</sup>, A. Schlegel<sup>2</sup>, P. Muiesan<sup>2</sup>, I. Capobianco<sup>3</sup>, S. Nadalin<sup>3</sup>, O. Torres<sup>4</sup>, A. Mehrabi<sup>5</sup>, G.A. Stavrou<sup>6, 7</sup>, K.J. Oldhafer<sup>6, 7</sup>, G. Lurje<sup>8</sup>, U. Neumann<sup>8</sup>, R. Robles-Campos<sup>9</sup>, R. Hernandez-Alejandro<sup>10, 11</sup>, M. Malago<sup>12</sup>, E. De Santibanes<sup>13</sup>, P.-A. Clavien<sup>1</sup>, H. Petrowsky<sup>1</sup>

<sup>1</sup>University Hospital Zurich, Department of Surgery and Transplantation, Zurich, Switzerland, <sup>2</sup>University Hospitals Birmingham NHS Foundation Trust, Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, <sup>3</sup>University Hospital Tübingen, Department for General, Visceral and Transplant Surgery, Tübingen, Germany, <sup>4</sup>Universidade Federal do Maranhão, Department of Surgery, Sao Luis-MA, Brazil, <sup>5</sup>University of Heidelberg, Department of General, Visceral, and Transplantation Surgery, Heidelberg, Germany, <sup>6</sup>Asklepios Hospital Barmbek, Department of General and Abdominal Surgery, Hamburg, Germany, <sup>7</sup>Semmelweis University Budapest, Campus Hamburg, Germany, <sup>8</sup>University Hospital Aachen, RWTH Aachen, Department of General, Visceral and Transplantation Surgery, Aachen, Germany, <sup>9</sup>Virgen de la Arrixaca Clinic and University Hospital, Department of Surgery and Liver and Pancreas Transplantation, Murcia, Spain, <sup>10</sup>London Health Sciences Centre, Department of Surgery, Division of HPB Surgery and Liver Transplantation, London, Ontario, Canada, <sup>11</sup>University of Rochester, Division of Transplantation, Hepatobiliary Surgery, Rochester, United States, <sup>12</sup>University College London, Royal Free Hospitals, Department of HPB- and Liver Transplantation Surgery, London, United Kingdom, <sup>13</sup>Italian Hospital Buenos Aires, Department of Surgery, Division of HPB Surgery, Liver Transplant Unit, Buenos Aires, Argentina

❑ Autores de 8 países (1 Brasileiro)

❑ Estratégia para tornar o procedimento mais seguro

## ASSOCIATING LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS): THE BRAZILIAN EXPERIENCE

*Ligadura da veia porta associada à bipartição do fígado para hepatectomia em dois estágios (ALPPS): experiência Brasileira*

Orlando Jorge Martins **TORRES**<sup>1</sup>, Eduardo de Souza Martins **FERNANDES**<sup>2</sup>, Cassio Virgilio Cavalcante **OLIVEIRA**<sup>3</sup>,  
Cristiano Xavier **LIMA**<sup>4</sup>, Fabio Luiz **WAECHTER**<sup>5</sup>, Jose Maria Assunção **MORAES-JUNIOR**<sup>1</sup>,  
Marcelo Moura **LINHARES**<sup>6</sup>, Rinaldo Danese **PINTO**<sup>7</sup>, Paulo **HERMAN**<sup>8</sup>, Marcel Autran Cesar **MACHADO**<sup>9</sup>

❑ 83 yr

❑ Sarcoma

❑ Additional surgery:

- Colectomy

Pancreatoduodenectomy

❑ 12.8 % Mortality

## ASSOCIATING LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS): THE BRAZILIAN EXPERIENCE

*Ligadura da veia porta associada à bipartição do fígado para hepatectomia em dois estágios (ALPPS): experiência Brasileira*

Orlando Jorge Martins **TORRES**<sup>1</sup>, Eduardo de Souza Martins **FERNANDES**<sup>2</sup>, Cassio Virgilio Cavalcante **OLIVEIRA**<sup>3</sup>,  
Cristiano Xavier **LIMA**<sup>4</sup>, Fabio Luiz **WAECHTER**<sup>5</sup>, Jose Maria Assunção **MORAES-JUNIOR**<sup>1</sup>,  
Marcelo Moura **LINHARES**<sup>6</sup>, Rinaldo Danese **PINTO**<sup>7</sup>, Paulo **HERMAN**<sup>8</sup>, Marcel Autran Cesar **MACHADO**<sup>9</sup>

TABLE 1 - Complications after ALPPS approach

| Complications             | n | %    |
|---------------------------|---|------|
| Surgical site infection   | 8 | 20.5 |
| Ascites                   | 5 | 12.8 |
| Biliary fistula           | 4 | 10.2 |
| Pneumonia                 | 4 | 10.2 |
| Abdominal hernia          | 4 | 10.2 |
| Sepsis                    | 3 | 7.7  |
| Acute renal failure       | 2 | 5.1  |
| Bile duct injury          | 1 | 2.5  |
| Hepatic artery thrombosis | 1 | 2.5  |
| Acute liver failure       | 1 | 2.5  |
| Others                    | 9 | 23.0 |

❑ High risk score

❑ 4 patients

❑ 35 pacientes

❑ 1 óbito

❑ Mortal 2,86%

Ativar o Windows



**Obrigado !**



**Lençóis Maranhenses**